Sunday, February 13, 2022 2:24:35 PM
"(Maybe hire someone else from AmerisourceBergen to plan and organize the Buyout)"
Opportunity and Summary of Position:
Director of Financial Planning and Analysis will oversee the budget and finances of the company.
Reporting Relationships:
The Director of Financial Planning and Analysis at Outlook Therapeutics’ reports to the Financial Controller.
Position Responsibilities:• Forecasting, budgeting and long-range planning.• Decision support on initiatives and investments.• Performance analysis and management reporting.• Identify and drive profitability and cash flow improvements.• Preparing revenue projections and forecasting expenditure.• Link revenue forecasts with margin expectations.• Develop mid and long-range strategic plans.• Ensure investment strategies support cost savings.• Evaluate resource investments and provide recommendations.• Track business case results with closed loop to forecast and budget• Produce KPIs with scorecards for each cost category.• Perform analysis on all operating metrics and KPIs.• Results v budget with variance analysis and explanation. Evaluation of gap closure initiatives with tracking• Support Business unit and product profitability. Business Unit and Product margin views• Synergy and integration tracking. Drive process and organizational efficiency initiatives• Creates and implements business plans, projections, budgets, and other single and multi-year analysis projects.• Collaborates with other departments and senior leadership to establish an effective budget for the organization.• Provides relevant financial information to executive management team.• Communicates with management on behalf of the Chief Financial Officer.• Collaborates with the Chief Financial Officer and Financial Controller and assists as needed for all matters related to the organization’s financial, planning, and budget programs.• Performs other related duties as assigned.
**Candidate Qualifications:**The company is seeking an individual with the following qualifications and who is willing to make a long-term commitment to the organization:
Education/Certificationo Bachelor’s degree in accounting, finance or business required; MBA and/or CPA preferred.o Bachelor’s degree with 10-15+ years of experience in Finance and Business management roles, preferably FP&A.o Strong presentation, interpersonal, and written skills.o Leadership experience in people management, program management and a strong track record of effectiveness in execution, time management, and influencing to deliver objectives.o Strong execution orientation and ability to inspire action.
Qualifications and Skillso Exceptional verbal and written communication skills.o Excellent organizational skills and attention to detail.o Ability to prioritize and delegate tasks.o Ability to analyze and evaluate budgets and financial models.o Ability to create and present ideas and budgets in a variety of formats.o Ability to maintain confidential records.o Proficient with Microsoft Office Suite or related software as needed to create and analyze budgets.
CompensationAn attractive compensation package will be offered to the successful candidate. It will include a competitive base salary and incentive bonus. A benefits package customary to the position will also be provided including 401k match, medical and dental.Outlook Therapeutics is an equal opportunity employer.
Interested applicants can send resumes to: HR@outlooktherapeutics.com
Source: https://outlooktherapeutics.com/director-fpa/
Recent OTLK News
- Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase • GlobeNewswire Inc. • 04/29/2024 01:00:00 PM
- Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million • GlobeNewswire Inc. • 04/15/2024 08:15:00 PM
- Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD • GlobeNewswire Inc. • 03/22/2024 11:35:35 AM
- Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million • GlobeNewswire Inc. • 03/18/2024 09:10:05 PM
- Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 03/12/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:18:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:11:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:08:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:16:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:10:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:40:14 PM
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update • GlobeNewswire Inc. • 02/14/2024 01:05:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 02/08/2024 12:00:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/08/2024 11:59:42 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/31/2024 09:01:44 PM
- Outlook Therapeutics® Doses First Subject in NORSE EIGHT • GlobeNewswire Inc. • 01/31/2024 01:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/29/2024 10:00:29 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/24/2024 10:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 11:02:07 AM
- Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010 • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/22/2023 10:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:15:27 PM
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU • GlobeNewswire Inc. • 12/22/2023 01:05:00 PM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM